These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36448319)

  • 1. Safely use of omalizumab during SARS-CoV-2 infection in patients with chronic spontaneous urticaria.
    Özdemir Ö; Dikici Ü
    J Cosmet Dermatol; 2023 Jan; 22(1):26-27. PubMed ID: 36448319
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study.
    Abduelmula A; Georgakopoulos JR; Mufti A; Devani AR; Gooderham MJ; Hong CH; Jain V; Lansang P; Vender R; Prajapati VH; Yeung J
    J Cutan Med Surg; 2022; 26(3):319-320. PubMed ID: 34587789
    [No Abstract]   [Full Text] [Related]  

  • 3. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on "Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab".
    Abdelmaksoud A; Goldust M; Vestita M
    Int J Dermatol; 2020 Nov; 59(11):1417-1418. PubMed ID: 32989738
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.
    Ayhan E; Öztürk M; An İ; Bekçİbaşi M
    Int J Dermatol; 2021 Feb; 60(2):253-254. PubMed ID: 33332576
    [No Abstract]   [Full Text] [Related]  

  • 6. Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.
    Tonacci A; Nettis E; Asero R; Rossi O; Tontini C; Gangemi S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(3):100-103. PubMed ID: 32108461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
    Dortas Junior S; Azizi G; Valle S
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.
    Passante M; Napolitano M; Dastoli S; Bennardo L; Fabbrocini G; Nisticò SP; Patruno C
    Dermatol Ther; 2021 Nov; 34(6):e15111. PubMed ID: 34427028
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience.
    Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A
    An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165
    [No Abstract]   [Full Text] [Related]  

  • 10. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
    Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
    [No Abstract]   [Full Text] [Related]  

  • 11. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria.
    Maurer M; Kolkhir P; Moñino-Romero S; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668
    [No Abstract]   [Full Text] [Related]  

  • 12. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?
    Thiede RM; Fazel M; MacDonald KM; Abraham I
    Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375
    [No Abstract]   [Full Text] [Related]  

  • 13. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
    Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
    Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series.
    Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440
    [No Abstract]   [Full Text] [Related]  

  • 15. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
    Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
    J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab.
    Criado PR; Criado RFJ; Pincelli TP; Yoshimoto TA; Naufal GGA; Abdalla BMZ
    Int J Dermatol; 2020 Oct; 59(10):1294-1295. PubMed ID: 32808279
    [No Abstract]   [Full Text] [Related]  

  • 17. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
    Ghazanfar MN; Bartko EA; Arildsen NS; Poulsen LK; Jensen BM; Enevold C; Holm JG; Woetmann A; Ødum N; Thomsen SF
    Clin Exp Allergy; 2022 May; 52(5):715-718. PubMed ID: 35278253
    [No Abstract]   [Full Text] [Related]  

  • 18. Retrospective evaluation of patients with chronic spontaneous urticaria using omalizumab during the COVID-19 pandemic.
    Koç Yıldırım S; Demirel Öğüt N; Erbağcı E
    J Cosmet Dermatol; 2022 Feb; 21(2):431-434. PubMed ID: 34982508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
    Farrah G; Stevenson B; Lie K; Brusch A
    Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Belbezier A; Boccon-Gibod I; Bouillet L
    Eur J Dermatol; 2021 Feb; 31(1):86-87. PubMed ID: 33772528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.